BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15927827)

  • 1. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer.
    Sharma R; Beith J; Hamilton A
    Breast; 2005 Jun; 14(3):181-91. PubMed ID: 15927827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
    ; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
    Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
    Hubalek M; Brantner C; Marth C
    Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?].
    Daguenet E; Jmour O; Vallard A; Guy JB; Jacquin JP; Méry B; Magné N
    Bull Cancer; 2019 Apr; 106(4):342-353. PubMed ID: 30853114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
    Li HC; Wen XF; Hou YF; Shen KW; Wu J; Lu JS; Shen ZZ; Shao ZM
    Asian J Surg; 2003 Jul; 26(3):163-8. PubMed ID: 12925292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.
    Takuwa H; Saji S; Takada M; Takahara S; Yamauchi A
    Breast Dis; 2018; 37(4):185-190. PubMed ID: 29578459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
    Prowell TM; Davidson NE
    Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of endocrine treatments for breast cancer on health-related quality of life.
    Buijs C; de Vries EG; Mourits MJ; Willemse PH
    Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian suppression for early breast cancer.
    Wilcken N; Stockler M
    Lancet; 2007 May; 369(9574):1668-70. PubMed ID: 17512837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.